Hypoglycemia and Cardiovascular Risks
TLDR
The effects of hypoglycemia on the CV system is reviewed, how this major metabolic stress could precipitate major vascular events such as myocardial infarction and stroke, and its potential role in these recent clinical studies are reviewed.Abstract:
Although hypoglycemia is the most common side effect of insulin therapy in diabetes and its morbidity is well known, for many years, the potentially life-threatening effects of hypoglycemia on the cardiovascular (CV) system have either been overlooked or have been dismissed as inconsequential to people with insulin-treated type 2 diabetes. This scenario may possibly be a consequence of the persisting misconception that this population is seldom exposed to severe hypoglycemia, defined as any episode that requires external assistance for recovery, whereas self-treated events are classified as “mild” (1). This myth was firmly repudiated by the findings of the large prospective study by the U.K. Hypoglycemia Study Group (2), which demonstrated that severe hypoglycemia is a common problem in insulin-treated type 2 diabetes and that the incidence increases with duration of insulin therapy. However, evidence for CV morbidity associated with hypoglycemia has been predominantly hypothetical and anecdotal (1,3). The potential dangers of intensive treatment regimens and strict glycemic control in people with type 2 diabetes who have CV disease (CVD) have now been highlighted by the disconcerting outcomes of recent studies (4–6), in which hypoglycemia was implicated in the excess mortality that was observed in some of these trials. It is therefore timely to review the effects of hypoglycemia on the CV system, how this major metabolic stress could precipitate major vascular events such as myocardial infarction and stroke, and its potential role in these recent clinical studies.
In the adult human, acute hypoglycemia causes pronounced physiological responses as a consequence of autonomic activation, principally of the sympatho-adrenal system, and results in end-organ stimulation and a profuse release of epinephrine (adrenaline). This profound autonomic stimulus provokes hemodynamic changes, the important consequences of which are to maintain the supply of glucose to the brain and promote the hepatic …read more
Citations
More filters
Journal ArticleDOI
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino,Peter J. Grant,Victor Aboyans,Clifford J Bailey,Antonio Ceriello,Victoria Delgado,Massimo Federici,Gerasimos Filippatos,Diederick E. Grobbee,Tina Birgitte Hansen,Heikki V. Huikuri,I. Johansson,Peter Jüni,Maddalena Lettino,Nikolaus Marx,Linda Mellbin,Carl J. Östgren,Bianca Rocca,Marco Roffi,Naveed Sattar,Petar M. Seferović,Miguel Sousa-Uva,Paul Valensi,David C Wheeler +23 more
TL;DR: The second iteration of the European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) joining forces to write guidelines on the management of diabetes mellitus (DM), pre-diabetes, and cardiovascular disease (CVD), designed to assist clinicians and other healthcare workers to make evidence-based management decisions.
Journal ArticleDOI
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)
Journal ArticleDOI
Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence A Scientific Statement From the American Heart Association and the American Diabetes Association
Caroline S. Fox,Sherita Hill Golden,Cheryl A.M. Anderson,George A. Bray,Lora E. Burke,Ian H. de Boer,Prakash Deedwania,Robert H. Eckel,Abby G. Ershow,Judith E. Fradkin,Silvio E. Inzucchi,Mikhail Kosiborod,Robert G. Nelson,Mahesh J. Patel,Michael Pignone,Laurie Quinn,Philip R. Schauer,Elizabeth Selvin,Dorothea K. Vafiadis +18 more
TL;DR: A synthesis of the recent literature, new guidelines, and clinical targets, including screening for kidney and subclinical cardiovascular disease for the contemporary management of patients with type 2 diabetes mellitus are presented.
Journal ArticleDOI
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Steven P. Marso,Darren K. McGuire,Bernard Zinman,Neil Poulter,Scott S. Emerson,Thomas R. Pieber,Richard E. Pratley,Poul Martin Haahr,Martin Lange,Kirstine Brown-Frandsen,Alan C. Moses,Simon Skibsted,Kajsa Kvist,John B. Buse +13 more
TL;DR: Among patients with type 2 diabetes at high risk for cardiovascular events, degludec was noninferior to glargine with respect to the incidence of major cardiovascular events.
Journal ArticleDOI
Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications
TL;DR: Prevention of hypoglycaemia is an important part of diabetes mellitus management and strategies include patient education, glucose monitoring, appropriate adjustment of diet and medications in relation to everyday circumstances including physical exercise, and the application of new technologies such as real-time continuous glucose monitoring.
References
More filters
Journal ArticleDOI
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein,Michael Miller,Robert P. Byington,David C. Goff,J. Thomas Bigger,John B. Buse,William C. Cushman,Saul Genuth,Faramarz Ismail-Beigi,Faramarz Ismail-Beigi,Richard H. Grimm,Jeffrey L. Probstfield,Denise G. Simons-Morton,William T. Friedewald +13 more
TL;DR: In this paper, the authors investigated whether intensive therapy to target normal glycated hemoglobin levels would reduce cardiovascular events in patients with type 2 diabetes who had either established cardiovascular disease or additional cardiovascular risk factors.
Journal ArticleDOI
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Anushka Patel,Stephen MacMahon,John Chalmers,Bruce Neal,Laurent Billot,Mark Woodward,Mark Woodward,Michel Marre,Mark E. Cooper,Paul Glasziou,Paul Glasziou,Diederick E. Grobbee,Pavel Hamet,Stephen B. Harrap,Simon Heller,Lisheng Liu,Giuseppe Mancia,Carl Erik Mogensen,C. Y. Pan,Neil R Poulter,Anthony Rodgers,Bryan Williams,Severine Bompoint,Bastiaan E. de Galan,Bastiaan E. de Galan,Rohina Joshi,F. Travert +26 more
TL;DR: A strategy of intensive glucose control, involving gliclazide (modified release) and other drugs as required, that lowered the glycated hemoglobin value to 6.5% yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events, primarily as a consequence of a 21%relative reduction in nephropathy.
Journal ArticleDOI
Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
William C. Duckworth,Carlos Abraira,Thomas E. Moritz,Domenic J. Reda,Nicholas V. Emanuele,Peter D. Reaven,Franklin J. Zieve,Jennifer B. Marks,Stephen N. Davis,Rodney A. Hayward,Stuart R. Warren,Steven Goldman,Madeline McCarren,Mary Ellen Vitek,William G. Henderson,Grant D. Huang +15 more
TL;DR: Intensive glucose control in patients with poorly controlled type 2 diabetes had no significant effect on the rates of major cardiovascular events, death, or microvascular complications with the exception of progression of albuminuria.
Journal ArticleDOI
Intensive versus conventional glucose control in critically ill patients.
Nice-Sugar Study Investigators,Dean R. Chittock,Steve Su,D. Blair,Denise Foster,Rinaldo Bellomo,Deborah J. Cook,Vinay Dhingra,Peter Dodek,Paul C. Hébert,William R. Henderson,Stephane Heritier,Daren K. Heyland,Colin McArthur,Ellen McDonald,Imogen Mitchell,Robyn Norton,J. Potter,Bruce G. Robinson,Juan J. Ronco +19 more
TL;DR: In this large, international, randomized trial, it was found that intensive glucose control increased mortality among adults in the ICU: a blood glucose target of 180 mg or less per deciliter resulted in lower mortality than did a target of 81 to 108 mg perDeciliter.
Journal ArticleDOI
Effects of Intensive Glucose Lowering in Type 2 Diabetes
TL;DR: The use of intensive therapy to target normal glycated hemoglobin levels for 3.5 years increased mortality and did not significantly reduce major cardiovascular events, identifying a previously unrecognized harm of intensive glucose lowering in high-risk patients with type 2 diabetes.
Related Papers (5)
Effects of intensive glucose lowering in type 2 diabetes
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Anushka Patel,Stephen MacMahon,John Chalmers,Bruce Neal,Laurent Billot,Mark Woodward,Mark Woodward,Michel Marre,Mark E. Cooper,Paul Glasziou,Paul Glasziou,Diederick E. Grobbee,Pavel Hamet,Stephen B. Harrap,Simon Heller,Lisheng Liu,Giuseppe Mancia,Carl Erik Mogensen,C. Y. Pan,Neil R Poulter,Anthony Rodgers,Bryan Williams,Severine Bompoint,Bastiaan E. de Galan,Bastiaan E. de Galan,Rohina Joshi,F. Travert +26 more